News Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
6.205 ^USD	-12.23%		+0.89%	+182.05%

Dec. 09	Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants	RE
Dec. 08	Immix Biopharma Prices $100 Million Offering	MT

Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants	Dec. 09	RE
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	Dec. 09	GL
Immix Biopharma : Presentation (IMMX Corporate presentation December 2025)	Dec. 08	PU
Immix Biopharma Prices $100 Million Offering	Dec. 08	MT
Immix Biopharma Prices $100 Million Offering	Dec. 08	MT
Immix Biopharma prices offering of 19.1 million shares at $5.10 per share	Dec. 07	RE
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	Dec. 07	GL
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis	Dec. 07	GL
Immix Biopharma, Inc. Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-In-Class Therapy for Relapsed/Refractory AL Amyloidosis	Dec. 07	CI
Immix Biopharma : Presentation (IMMX Corporate presentation – November 2025)	Dec. 02	PU
Immix Biopharma : Presentation (IMMX Corporate presentation – December 2024)	Dec. 02	PU
Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	Nov. 12	CI
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch	Nov. 12	GL
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 07	CI
Immix Biopharma : Presentation (IMMX Corporate presentation November 2025)	Nov. 03	PU
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025	Nov. 03	GL
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference	Oct. 14	GL
Immix Biopharma : Presentation (IMMX Corporate presentation October 2025)	Oct. 08	PU
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting	Oct. 06	GL
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference	Oct. 01	GL
Immix Biopharma says that 50% enrollment has already been surpassed in NEXICART-2	Sep. 18	RE
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2	Sep. 18	GL
Immix Biopharma, Inc. Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory AL Amyloidosis Clinical Trial, NEXICART-2	Sep. 18	CI
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors	Sep. 11	GL
Immix Biopharma Gets Strategic Investment	Sep. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Filters